BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 21277618)

  • 1. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
    Perez-Alvarez R; Perez-de-Lis M; Diaz-Lagares C; Pego-Reigosa JM; Retamozo S; Bove A; Brito-Zeron P; Bosch X; Ramos-Casals M
    Semin Arthritis Rheum; 2011 Oct; 41(2):256-64. PubMed ID: 21277618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune diseases induced by TNF-targeted therapies.
    Ramos-Casals M; Brito-Zerón P; Soto MJ; Cuadrado MJ; Khamashta MA
    Best Pract Res Clin Rheumatol; 2008 Oct; 22(5):847-61. PubMed ID: 19028367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eternacept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease.
    Horai Y; Miyamura T; Shimada K; Takahama S; Minami R; Yamamoto M; Suematsu E
    J Clin Pharm Ther; 2012 Feb; 37(1):117-21. PubMed ID: 21128990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis.
    Nakashita T; Ando K; Kaneko N; Takahashi K; Motojima S
    BMJ Open; 2014 Aug; 4(8):e005615. PubMed ID: 25125479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary disorders induced by monoclonal antibodies in patients with rheumatologic autoimmune diseases.
    Ramos-Casals M; Perez-Alvarez R; Perez-de-Lis M; Xaubet A; Bosch X;
    Am J Med; 2011 May; 124(5):386-94. PubMed ID: 21531225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent.
    Koo BS; Hong S; Kim YJ; Kim YG; Lee CK; Yoo B
    Korean J Intern Med; 2015 Jan; 30(1):104-9. PubMed ID: 25589842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors.
    Deng A; Harvey V; Sina B; Strobel D; Badros A; Junkins-Hopkins JM; Samuels A; Oghilikhan M; Gaspari A
    Arch Dermatol; 2006 Feb; 142(2):198-202. PubMed ID: 16490847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.
    Ramos-Casals M; Brito-Zerón P; Muñoz S; Soria N; Galiana D; Bertolaccini L; Cuadrado MJ; Khamashta MA
    Medicine (Baltimore); 2007 Jul; 86(4):242-251. PubMed ID: 17632266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
    Atzeni F; Boiardi L; Sallì S; Benucci M; Sarzi-Puttini P
    Expert Rev Clin Immunol; 2013 Jul; 9(7):649-57. PubMed ID: 23899235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
    Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ;
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.
    Gómez-Reino JJ; Carmona L; Valverde VR; Mola EM; Montero MD;
    Arthritis Rheum; 2003 Aug; 48(8):2122-7. PubMed ID: 12905464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases.
    Régnier-Rosencher E; Farhi D; Lebrun A; Salliot C; Dougados M; Dupin N
    Dermatology; 2012; 224(1):72-83. PubMed ID: 22487697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.
    Toussirot E; Berthelot JM; Pertuiset E; Bouvard B; Gaudin P; Wendling D; le Noach J; Lohse A; Lecuyer E; Cri L
    J Rheumatol; 2009 Nov; 36(11):2421-7. PubMed ID: 19797509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
    Thyagarajan V; Norman H; Alexander KA; Napalkov P; Enger C
    Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis.
    Hagiwara K; Sato T; Takagi-Kobayashi S; Hasegawa S; Shigihara N; Akiyama O
    J Rheumatol; 2007 May; 34(5):1151-4. PubMed ID: 17444583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.